Stay updated with breaking news from Enterome Oncomimics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The use of the first-in-class, microbiome-derived therapeutic vaccine EO2401 in combination with nivolumab with or without bevacizumab produced clinical activity and was well tolerated in patients with progressive/recurrent glioblastoma.
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases, has announced that the first patient has been dosed in its phase 1/2 trial evaluating EO4010.
Brain Tumour Research’s worldwide research update includes a discovery from Queen Mary University of London which could benefit glioblastoma (GBM) patients.
Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022 Data highlights strong immune responses and early signs of clinical benefit, establishing proof-of-concept OncoMimics™ immunotherapy pipeline generate...
/PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug...